Journal Article

DZNE-2026-00751

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png Value of MRI Outcomes for Preventive and Early-Stage Trials in Spinocerebellar Ataxias 1 and 3.

Rezende, T. J. R. ; Petit, E. ; Park, Y. W. ; du Montcel, S. T. ; Joers, J. M. ; DuBois, J. M. ; Arnold, H. M. ; Povazan, M. ; Özdemir, I. ; Banan, G. ; Valabregue, R. ; Ehses, P.DZNE* ; Faber, J.DZNE* ; Onyike, C. U. ; Barker, P. B. ; Schmahmann, J. D. ; Ratai, E.-M. ; Subramony, S. H. ; Mareci, T. H. ; Bushara, K. O. ; Paulson, H. ; Klockgether, T.DZNE* ; Durr, A. ; Ashizawa, T. ; Lenglet, C. ; Öz, G. ; Investigators, R. (Collaboration Author)

2026
Wiley Chichester [u.a.]

This record in other databases:    

Please use a persistent id in citations: doi:10.1002/acn3.70325

Abstract: To examine the value of MRI outcomes as endpoints for preventive and early-stage trials of two polyglutamine spinocerebellar ataxias (SCAs).A cohort of 100 participants (23 SCA1, 63 SCA3, median Scale for the Assessment and Rating of Ataxia (SARA) score = 5, 42% preataxic, and 14 gene-negative controls) was scanned at 3T up to 6 times (median follow-up 3 years) in the READISCA study. Structural, microstructural, and neurochemical outcomes were assessed for sensitivity to change. Associations between change in MR and clinical and patient-reported outcomes were evaluated. Sample sizes were estimated for preventive trials (at preataxic stage) and early-stage trials using the most sensitive outcomes.Infratentorial volumes, middle cerebellar peduncle (MCP) diffusivities and select neurochemical outcomes were more sensitive to change than SARA in both SCAs with moderate-to-high effect sizes (Cohen's d ≥ 0.5). The pons volume was the most sensitive outcome at both preataxic (d = 1.09) and ataxic (d = 1.48) stages. The most sensitive MR measures overlapped between genotypes, except that SCA1 showed faster progression in the cerebellum and SCA3 in the pons. Changes in MCP diffusivities and pontine neurochemical measures were associated with changes in SARA and FARS-ADL (|r| = 0.28-0.47).The estimated sample sizes to detect a 50% reduction in progression with 80% power using the pons volume as primary outcome measure indicate the feasibility of preventive trials (n = 73 per arm in a 1-year trial) in common SCAs and predict a 6-fold reduction in required sample sizes relative to SARA in early interventional trials. These findings support the use of MRI endpoints in early-stage SCA trials.

Keyword(s): Humans (MeSH) ; Female (MeSH) ; Spinocerebellar Ataxias: diagnostic imaging (MeSH) ; Spinocerebellar Ataxias: prevention & control (MeSH) ; Spinocerebellar Ataxias: pathology (MeSH) ; Male (MeSH) ; Magnetic Resonance Imaging: standards (MeSH) ; Middle Aged (MeSH) ; Adult (MeSH) ; Machado-Joseph Disease: diagnostic imaging (MeSH) ; Machado-Joseph Disease: pathology (MeSH) ; Machado-Joseph Disease: prevention & control (MeSH) ; Outcome Assessment, Health Care: standards (MeSH) ; Pons: diagnostic imaging (MeSH) ; Pons: pathology (MeSH) ; Disease Progression (MeSH) ; Middle Cerebellar Peduncle: diagnostic imaging (MeSH) ; Middle Cerebellar Peduncle: pathology (MeSH) ; MRI ; longitudinal ; spinocerebellar ataxia

---

Contributing Institute(s):

1. MR Physics (AG Stöcker)
2. Artificial Intelligence in Medicine (AG Reuter)
3. Clinical Research Coordination (Clinical Research (Bonn))
4. Patient Studies (Bonn) (Patient Studies (Bonn))

Research Program(s):

1. 354 - Disease Prevention and Healthy Aging (POF4-354) (POF4-354)
2. 353 - Clinical and Health Care Research (POF4-353) (POF4-353)

---

Database coverage:
; ; Article Processing Charges ; Clarivate Analytics Master Journal List ; DEAL Wiley ; DOAJ Seal ; Ebsco Academic Search ; Essential Science Indicators ; Fees ; IF >= 5 ; JCR ; SCOPUS ; Science Citation Index Expanded ; Web of Science Core Collection

---